Annual Cash & Cash Equivalents
$52.23 M
-$82.96 M-61.36%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual cash & cash equivalents is $52.23 million, with the most recent change of -$82.96 million (-61.36%) on December 31, 2023.
- During the last 3 years, KPTI annual cash & cash equivalents has fallen by -$33.69 million (-39.21%).
- KPTI annual cash & cash equivalents is now -72.58% below its all-time high of $190.46 million, reached on December 31, 2021.
Performance
KPTI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$72.83 M
-$11.95 M-14.09%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly cash and cash equivalents is $72.83 million, with the most recent change of -$11.95 million (-14.09%) on September 30, 2024.
- Over the past year, KPTI quarterly cash and cash equivalents has dropped by -$11.95 million (-14.09%).
- KPTI quarterly cash and cash equivalents is now -67.94% below its all-time high of $227.13 million, reached on September 30, 2014.
Performance
KPTI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
KPTI Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -61.4% | -14.1% |
| 3 y3 years | -39.2% | -47.0% |
| 5 y5 years | -55.7% | -56.6% |
KPTI Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -72.6% | at low | -61.8% | +137.8% |
| 5 y | 5-year | -72.6% | at low | -64.0% | +137.8% |
| alltime | all time | -72.6% | >+9999.0% | -67.9% | >+9999.0% |
Karyopharm Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $72.83 M(-14.1%) |
| Jun 2024 | - | $84.77 M(+176.8%) |
| Mar 2024 | - | $30.63 M(-41.4%) |
| Dec 2023 | $52.23 M(-61.4%) | $52.23 M(+19.6%) |
| Sep 2023 | - | $43.66 M(-46.0%) |
| Jun 2023 | - | $80.89 M(-3.8%) |
| Mar 2023 | - | $84.06 M(-37.8%) |
| Dec 2022 | $135.19 M(-29.0%) | $135.19 M(+89.5%) |
| Sep 2022 | - | $71.35 M(-13.2%) |
| Jun 2022 | - | $82.25 M(-46.3%) |
| Mar 2022 | - | $153.26 M(-19.5%) |
| Dec 2021 | $190.46 M(+121.7%) | $190.46 M(+38.6%) |
| Sep 2021 | - | $137.40 M(-2.8%) |
| Jun 2021 | - | $141.31 M(+59.7%) |
| Mar 2021 | - | $88.47 M(+3.0%) |
| Dec 2020 | $85.92 M(-33.3%) | $85.92 M(+4.4%) |
| Sep 2020 | - | $82.30 M(-20.2%) |
| Jun 2020 | - | $103.10 M(-49.0%) |
| Mar 2020 | - | $202.25 M(+57.0%) |
| Dec 2019 | $128.86 M(+9.2%) | $128.86 M(-23.3%) |
| Sep 2019 | - | $168.00 M(+122.4%) |
| Jun 2019 | - | $75.55 M(-9.5%) |
| Mar 2019 | - | $83.51 M(-29.2%) |
| Dec 2018 | $118.02 M | $118.02 M(+16.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2018 | - | $101.60 M(-14.6%) |
| Jun 2018 | - | $118.97 M(+217.3%) |
| Mar 2018 | - | $37.50 M(-45.7%) |
| Dec 2017 | $69.00 M(+38.9%) | $69.00 M(+26.7%) |
| Sep 2017 | - | $54.45 M(-1.7%) |
| Jun 2017 | - | $55.38 M(+116.5%) |
| Mar 2017 | - | $25.58 M(-48.5%) |
| Dec 2016 | $49.66 M(-14.9%) | $49.66 M(+13.1%) |
| Sep 2016 | - | $43.91 M(+16.4%) |
| Jun 2016 | - | $37.72 M(-10.6%) |
| Mar 2016 | - | $42.19 M(-27.7%) |
| Dec 2015 | $58.36 M(-61.3%) | $58.36 M(+34.2%) |
| Sep 2015 | - | $43.50 M(+79.5%) |
| Jun 2015 | - | $24.23 M(-52.9%) |
| Mar 2015 | - | $51.45 M(-65.8%) |
| Dec 2014 | $150.61 M(-3.4%) | $150.61 M(-33.7%) |
| Sep 2014 | - | $227.13 M(+71.7%) |
| Jun 2014 | - | $132.31 M(-8.7%) |
| Mar 2014 | - | $144.89 M(-7.1%) |
| Dec 2013 | $155.97 M(>+9900.0%) | $155.97 M(+194.7%) |
| Sep 2013 | - | $52.93 M(-14.2%) |
| Jun 2013 | - | $61.67 M(>+9900.0%) |
| Dec 2012 | $391.00 K(-94.0%) | $391.00 K |
| Dec 2011 | $6.51 M | - |
FAQ
- What is Karyopharm Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual cash & cash equivalents year-on-year change?
- What is Karyopharm Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Karyopharm Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of KPTI is $52.23 M
What is the all time high annual cash & cash equivalents for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual cash & cash equivalents is $190.46 M
What is Karyopharm Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, KPTI annual cash & cash equivalents has changed by -$82.96 M (-61.36%)
What is Karyopharm Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KPTI is $72.83 M
What is the all time high quarterly cash and cash equivalents for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly cash and cash equivalents is $227.13 M
What is Karyopharm Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, KPTI quarterly cash and cash equivalents has changed by -$11.95 M (-14.09%)